Tag Archives: NYSE:JNJ

The Exec VP, Chief Scientific Off of Johnson & Johnson is Exercising Options

Yesterday, the Exec VP, Chief Scientific Off of Johnson & Johnson, Paulus Stoffels, exercised options of Johnson & Johnson for $20.17M. Following Paulus Stoffels’ last JNJ Sell transaction on July 26, 2017, the stock climbed by 3.8%. Based on Johnson

BTIG Keeps a Sell Rating on Johnson & Johnson

In a report released yesterday, Dane Leone from BTIG reiterated a Sell rating on Johnson & Johnson (NYSE: JNJ), with a price target of $110. The company’s shares closed yesterday at $141.83. Leone wrote: “Present – Starting to Outweigh Macro

Credit Suisse Keeps a Hold Rating on Johnson & Johnson

In a report released yesterday, Vamil Divan from Credit Suisse maintained a Hold rating on Johnson & Johnson (NYSE: JNJ), with a price target of $154. The company’s shares closed yesterday at $148.14, close to its 52-week high of $148.32.

Wells Fargo Believes Johnson & Johnson (NYSE: JNJ) Won’t Stop Here

In a report released today, Larry Biegelsen from Wells Fargo reiterated a Buy rating on Johnson & Johnson (NYSE: JNJ), with a price target of $160. The company’s shares opened today at $144.99, close to its 52-week high of $146.15.

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), Alder Biopharmaceuticals (NASDAQ: ALDR) and Zimmer Biomet Holdings (NYSE: ZBH)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Johnson & Johnson (NYSE: JNJ), Alder Biopharmaceuticals (NASDAQ: ALDR) and Zimmer Biomet Holdings (NYSE: ZBH) with bullish sentiments. Johnson & Johnson (NYSE:

Johnson & Johnson Receives a Hold from Barclays

Barclays analyst Geoff Meacham maintained a Hold rating on Johnson & Johnson (NYSE: JNJ) today and set a price target of $148. The company’s shares opened today at $140.79, close to its 52-week high of $141.58. According to TipRanks.com, Meacham